Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors

Inclusion Criteria

• •Pathologic (histologic or cytologic) confirmation of metastatic or locally advanced solid tumor.
• •Patients who have experienced disease progression after receiving appropriate standard / approved chemotherapy and for whom no further standard or palliative treatment measures exist, or who have chosen to decline standard or palliative treatment.
• •One or more tumors measurable by RECIST criteria.
• •Karnofsky performance status ≥ 70%.
• •Recovery from any toxic or other effects of all previous therapy, including radiation, chemotherapy and surgery.
• •Negative serum or urine pregnancy test result in women of childbearing potential.
• •For men and women of child-producing potential, agreement to use effective contraception (hormonal or barrier birth control or abstinence) from the time of screening before study entry and throughout study participation.